Account
Articles
17.05.2022
Is NRDL inclusion in China really the golden ticke...

Introduction As the most populous country in the world with 1.4 billion inhabitants, China has the p...

Read more
Articles
11.05.2022
How are countries in South-East Asia establishing ...

Introduction Health Technology Assessment (HTA) implementation has been historically slow in Asia co...

Read more
Articles
03.05.2022
What are the top 5 considerations to be aware of b...

Introduction: Brazil is a market of 210 million people Brazil is the largest country in South Americ...

Read more
Articles
28.04.2022
Regulators are giving early access to medicines, b...

Introduction Early Access Programs (EAPs) help to give people with life threatening or seriously deb...

Read more
Articles
25.04.2022
What do France’s ATU reforms mean for manufa...

Introduction On 1 July 2021, France made changes to its long-standing Authorization for Temporary Us...

Read more
Articles
19.04.2022
Could Brexit lead to earlier access to medicines f...

Introduction Following Brexit, regulatory oversight in the UK has switched from the European Medicin...

Read more
Articles
13.04.2022
How do you win the race to market? Our top conside...

Introduction Early Access Programs, also known as special access programs, give patients access to m...

Read more
Articles
28.03.2022
Correlating value with price in the US oncology ma...

An affordable and sustainable market access landscape is key to ensure patient access to life-saving...

Read more
Articles
16.03.2022
The impacts of Market Access combination pricing

We explore why combination pricing is an issue in the oncology space and why payers and manufacturer...

Read more
Articles
10.03.2022
Orphan status higher prices in the UK

Beyond the regulatory level, a well-recognised challenge for companies launching drugs in orphan dis...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.